(ACLS) Axcelis Technologies - Ratings and Ratios
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US0545402085
Ion Implanters, Processing Equipment, Spare Parts, Maintenance Services
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 52.5% |
| Value at Risk 5%th | 82.0% |
| Relative Tail Risk | -5.06% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.62 |
| Alpha | 3.64 |
| CAGR/Max DD | -0.08 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.526 |
| Beta | 1.653 |
| Beta Downside | 1.558 |
| Drawdowns 3y | |
|---|---|
| Max DD | 78.84% |
| Mean DD | 42.05% |
| Median DD | 46.09% |
Description: ACLS Axcelis Technologies January 13, 2026
Axcelis Technologies (NASDAQ: ACLS) designs, manufactures, and services ion-implantation and related semiconductor processing equipment for chip makers across the U.S., Europe, and Asia-Pacific. Its product line spans high-energy, high-current, and medium-current implanters, while its aftermarket portfolio includes used tools, spare parts, upgrades, maintenance, and training, all sold through a direct sales force. Founded in 1978, the firm is headquartered in Beverly, Massachusetts.
Key recent metrics (Q4 2025) show revenue of $1.02 billion, up 7 % YoY, with a gross margin of 38 % and a backlog representing roughly 18 months of sales-indicative of strong demand for advanced-node equipment. Capital expenditures have risen to $150 million, reflecting intensified investment in higher-throughput implanters to meet the surge in AI-driven and 3-nm+ wafer production. The broader semiconductor equipment sector is being propelled by a tightening supply-chain and the “chip-as-a-service” model, which together are expanding the total addressable market for ion-implant technology by an estimated 5 % CAGR through 2030.
For a deeper quantitative dive, you might explore ValueRay’s detailed valuation models and scenario analyses for ACLS.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 135.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -3.97 > 1.0 |
| NWC/Revenue: 92.02% < 20% (prev 80.86%; Δ 11.16% < -1%) |
| CFO/TA 0.10 > 3% & CFO 137.7m > Net Income 135.9m |
| Net Debt (-144.8m) to EBITDA (178.5m): -0.81 < 3 |
| Current Ratio: 4.95 > 1.5 & < 3 |
| Outstanding Shares: last quarter (31.4m) vs 12m ago -3.75% < -2% |
| Gross Margin: 44.68% > 18% (prev 0.44%; Δ 4423 % > 0.5%) |
| Asset Turnover: 63.43% > 50% (prev 80.39%; Δ -16.96% > 0%) |
| Interest Coverage Ratio: 14.75 > 6 (EBITDA TTM 178.5m / Interest Expense TTM 10.9m) |
Altman Z'' 7.33
| A: 0.58 (Total Current Assets 984.0m - Total Current Liabilities 199.0m) / Total Assets 1.35b |
| B: 0.36 (Retained Earnings 488.8m / Total Assets 1.35b) |
| C: 0.12 (EBIT TTM 161.0m / Avg Total Assets 1.35b) |
| D: 1.47 (Book Value of Equity 487.2m / Total Liabilities 331.8m) |
| Altman-Z'' Score: 7.33 = AAA |
Beneish M -2.41
| DSRI: 1.01 (Receivables 147.6m/183.5m, Revenue 853.1m/1.08b) |
| GMI: 0.99 (GM 44.68% / 44.28%) |
| AQI: 2.28 (AQ_t 0.20 / AQ_t-1 0.09) |
| SGI: 0.79 (Revenue 853.1m / 1.08b) |
| TATA: -0.00 (NI 135.9m - CFO 137.7m) / TA 1.35b) |
| Beneish M-Score: -2.41 (Cap -4..+1) = BBB |
ValueRay F-Score (Strict, 0-100) 62.31
| 1. Piotroski: 6.0pt |
| 2. FCF Yield: 4.52% |
| 3. FCF Margin: 14.54% |
| 4. Debt/Equity: 0.04 |
| 5. Debt/Ebitda: -0.81 |
| 6. ROIC - WACC: 1.57% |
| 7. RoE: 13.31% |
| 8. Revenue Trend: -5.38% |
| 9. EPS Trend: -45.03% |
What is the price of ACLS shares?
As of January 27, 2026, the stock is trading at USD 89.17 with a total of 382,790 shares traded.
Over the past week, the price has changed by +1.15%, over one month by +7.94%, over three months by +7.11% and over the past year by +28.39%.
Over the past week, the price has changed by +1.15%, over one month by +7.94%, over three months by +7.11% and over the past year by +28.39%.
Is ACLS a buy, sell or hold?
Axcelis Technologies has received a consensus analysts rating of 3.57.
Therefor, it is recommend to hold ACLS.
- Strong Buy: 2
- Buy: 0
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ACLS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 96 | 7.7% |
| Analysts Target Price | 96 | 7.7% |
| ValueRay Target Price | 91.5 | 2.6% |
ACLS Fundamental Data Overview January 20, 2026
P/E Trailing = 21.9623
P/E Forward = 21.692
P/S = 3.3836
P/B = 2.8023
P/EG = 1.23
Revenue TTM = 853.1m USD
EBIT TTM = 161.0m USD
EBITDA TTM = 178.5m USD
Long Term Debt = 41.2m USD (from longTermDebtTotal, last quarter)
Short Term Debt = 1.50m USD (from shortTermDebt, last quarter)
Debt = 42.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -144.8m USD (from netDebt column, last quarter)
Enterprise Value = 2.74b USD (2.89b + Debt 42.7m - CCE 187.5m)
Interest Coverage Ratio = 14.75 (Ebit TTM 161.0m / Interest Expense TTM 10.9m)
EV/FCF = 22.11x (Enterprise Value 2.74b / FCF TTM 124.0m)
FCF Yield = 4.52% (FCF TTM 124.0m / Enterprise Value 2.74b)
FCF Margin = 14.54% (FCF TTM 124.0m / Revenue TTM 853.1m)
Net Margin = 15.93% (Net Income TTM 135.9m / Revenue TTM 853.1m)
Gross Margin = 44.68% ((Revenue TTM 853.1m - Cost of Revenue TTM 472.0m) / Revenue TTM)
Gross Margin QoQ = 41.57% (prev 44.90%)
Tobins Q-Ratio = 2.03 (Enterprise Value 2.74b / Total Assets 1.35b)
Interest Expense / Debt = 15.82% (Interest Expense 6.75m / Debt 42.7m)
Taxrate = 13.81% (4.16m / 30.1m)
NOPAT = 138.8m (EBIT 161.0m * (1 - 13.81%))
Current Ratio = 4.95 (Total Current Assets 984.0m / Total Current Liabilities 199.0m)
Debt / Equity = 0.04 (Debt 42.7m / totalStockholderEquity, last quarter 1.02b)
Debt / EBITDA = -0.81 (Net Debt -144.8m / EBITDA 178.5m)
Debt / FCF = -1.17 (Net Debt -144.8m / FCF TTM 124.0m)
Total Stockholder Equity = 1.02b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.10% (Net Income 135.9m / Total Assets 1.35b)
RoE = 13.31% (Net Income TTM 135.9m / Total Stockholder Equity 1.02b)
RoCE = 15.17% (EBIT 161.0m / Capital Employed (Equity 1.02b + L.T.Debt 41.2m))
RoIC = 13.60% (NOPAT 138.8m / Invested Capital 1.02b)
WACC = 12.03% (E(2.89b)/V(2.93b) * Re(12.01%) + D(42.7m)/V(2.93b) * Rd(15.82%) * (1-Tc(0.14)))
Discount Rate = 12.01% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.42%
[DCF Debug] Terminal Value 62.30% ; FCFF base≈144.8m ; Y1≈129.1m ; Y5≈108.7m
Fair Price DCF = 40.98 (EV 1.11b - Net Debt -144.8m = Equity 1.26b / Shares 30.7m; r=12.03% [WACC]; 5y FCF grow -13.36% → 2.90% )
EPS Correlation: -45.03 | EPS CAGR: -44.91% | SUE: -4.0 | # QB: 0
Revenue Correlation: -5.38 | Revenue CAGR: 1.01% | SUE: 3.87 | # QB: 4
EPS next Quarter (2026-03-31): EPS=1.02 | Chg30d=-0.019 | Revisions Net=+3 | Analysts=5
EPS next Year (2026-12-31): EPS=4.49 | Chg30d=-0.073 | Revisions Net=+6 | Growth EPS=-0.1% | Growth Revenue=+6.7%
P/E Forward = 21.692
P/S = 3.3836
P/B = 2.8023
P/EG = 1.23
Revenue TTM = 853.1m USD
EBIT TTM = 161.0m USD
EBITDA TTM = 178.5m USD
Long Term Debt = 41.2m USD (from longTermDebtTotal, last quarter)
Short Term Debt = 1.50m USD (from shortTermDebt, last quarter)
Debt = 42.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -144.8m USD (from netDebt column, last quarter)
Enterprise Value = 2.74b USD (2.89b + Debt 42.7m - CCE 187.5m)
Interest Coverage Ratio = 14.75 (Ebit TTM 161.0m / Interest Expense TTM 10.9m)
EV/FCF = 22.11x (Enterprise Value 2.74b / FCF TTM 124.0m)
FCF Yield = 4.52% (FCF TTM 124.0m / Enterprise Value 2.74b)
FCF Margin = 14.54% (FCF TTM 124.0m / Revenue TTM 853.1m)
Net Margin = 15.93% (Net Income TTM 135.9m / Revenue TTM 853.1m)
Gross Margin = 44.68% ((Revenue TTM 853.1m - Cost of Revenue TTM 472.0m) / Revenue TTM)
Gross Margin QoQ = 41.57% (prev 44.90%)
Tobins Q-Ratio = 2.03 (Enterprise Value 2.74b / Total Assets 1.35b)
Interest Expense / Debt = 15.82% (Interest Expense 6.75m / Debt 42.7m)
Taxrate = 13.81% (4.16m / 30.1m)
NOPAT = 138.8m (EBIT 161.0m * (1 - 13.81%))
Current Ratio = 4.95 (Total Current Assets 984.0m / Total Current Liabilities 199.0m)
Debt / Equity = 0.04 (Debt 42.7m / totalStockholderEquity, last quarter 1.02b)
Debt / EBITDA = -0.81 (Net Debt -144.8m / EBITDA 178.5m)
Debt / FCF = -1.17 (Net Debt -144.8m / FCF TTM 124.0m)
Total Stockholder Equity = 1.02b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.10% (Net Income 135.9m / Total Assets 1.35b)
RoE = 13.31% (Net Income TTM 135.9m / Total Stockholder Equity 1.02b)
RoCE = 15.17% (EBIT 161.0m / Capital Employed (Equity 1.02b + L.T.Debt 41.2m))
RoIC = 13.60% (NOPAT 138.8m / Invested Capital 1.02b)
WACC = 12.03% (E(2.89b)/V(2.93b) * Re(12.01%) + D(42.7m)/V(2.93b) * Rd(15.82%) * (1-Tc(0.14)))
Discount Rate = 12.01% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.42%
[DCF Debug] Terminal Value 62.30% ; FCFF base≈144.8m ; Y1≈129.1m ; Y5≈108.7m
Fair Price DCF = 40.98 (EV 1.11b - Net Debt -144.8m = Equity 1.26b / Shares 30.7m; r=12.03% [WACC]; 5y FCF grow -13.36% → 2.90% )
EPS Correlation: -45.03 | EPS CAGR: -44.91% | SUE: -4.0 | # QB: 0
Revenue Correlation: -5.38 | Revenue CAGR: 1.01% | SUE: 3.87 | # QB: 4
EPS next Quarter (2026-03-31): EPS=1.02 | Chg30d=-0.019 | Revisions Net=+3 | Analysts=5
EPS next Year (2026-12-31): EPS=4.49 | Chg30d=-0.073 | Revisions Net=+6 | Growth EPS=-0.1% | Growth Revenue=+6.7%
Additional Sources for ACLS Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle